AstraZeneca plans to cut 400 jobs in efforts to "streamline portions of its US commercial business."

The job losses are planned for the company’s US base in Delaware, although 70 of the 400 cuts will come from existing vacancies. Employees will be allowed to apply for voluntary redundancy, with decisions to be finalised by early December.

The move comes as AstraZeneca faces increasing pressure from generics as the company approaches a 2016 patent cliff, with its Crestor and Seroquel medications facing generic pressure when protection expires.

AztraZeneca North America head Rich Fante said: "These changes are necessary to build a leaner, more efficient company."

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now